A Fresh Look at the Mechanism of Isoniazid‐Induced Hepatotoxicity

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Clinical pharmacology and therapy

• Publication date

  2011-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/clpt.2010.355PMID 21412230
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Involvement of the immune system in idiosyncratic drug reactions.

  2011cited by this paper
• Severe isoniazid-associated liver injuries among persons being treated for latent tuberculosis infection - United States, 2004-2008.

  2010cited by this paper
• Mitochondrial involvement in drug-induced liver injury.

  2010cited by this paper
• D-penicillamine-induced autoimmunity: relationship to macrophage activation.

  2009cited by this paper
• Immunoallergic Drug-Induced Liver Injury in Humans

  2009cited by this paper
• Influence of glutathione S‐transferase M1 and T1 homozygous null mutations on the risk of antituberculosis drug‐induced hepatotoxicity in a Caucasian population

  2008cited by this paper
• A mechanistic study on the oxidation of hydrazides: application to the tuberculosis drug isoniazid.

  2008cited by this paper
• The impact of eosinophilia and hepatic necrosis on prognosis in patients with drug‐induced liver injury

  2007cited by this paper
• Prediction of in vivo potential for metabolic activation of drugs into chemically reactive intermediate: correlation of in vitro and in vivo generation of reactive intermediates and in vitro glutathione conjugate formation in rats and humans.

  2007cited by this paper
• Factors in hydrazine formation from isoniazid by paediatric and adult tuberculosis patients

  2005cited by this paper
• Idiosyncratic Liver Injury: Challenges and Approaches

  2005cited by this paper
• Inhibitory effect of antituberculosis drugs on human cytochrome P450-mediated activities.

  2004cited by this paper
• Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug‐induced hepatitis

  2003cited by this paper
• Polymorphism of the N‐acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug–induced hepatitis

  2002cited by this paper
• Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during antituberculosis treatment.

  2002cited by this paper
• Increased risk of antituberculosis drug‐induced hepatotoxicity in individuals with glutathione S‐transferase M1 ‘null’ mutation

  2001cited by this paper
• Role of hydrazine in the mechanism of isoniazid hepatotoxicity in rabbits

  1996cited by this paper
• Metabolism of isoniazid by activated leukocytes. Possible role in drug-induced lupus.

  1992cited by this paper
• Systemic lupus erythematosus induced by isoniazid.

  1992cited by this paper
• Toxic hepatitis with isoniazid and rifampin. A meta-analysis.

  1991cited by this paper
• Pharmacokinetics of the toxic hydrazino metabolites formed from isoniazid in humans.

  1985cited by this paper
• Plasma Hydrazine Concentrations in Man after Isoniazid and Hydralazine Administration

  1985cited by this paper
• Isoniazid hepatoxicity: the relationship between covalent binding and metabolism in vivo.

  1980cited by this paper
• Role of hydrazine in carcinogenesis.

  1979cited by this paper
• Hepatotoxicity: The adverse effects of drugs and other chemicals on the liver

  1978cited by this paper
• Isoniazid liver injury: clinical spectrum, pathology, and probable pathogenesis.

  1976cited by this paper
• Isoniazid and iproniazid: activation of metabolites to toxic intermediates in man and rat.

  1976cited by this paper
• Increased incidence of isoniazid hepatitis in rapid acetylators: possible relation to hydrazine metabolites

  1975cited by this paper
• Isoniazid-associated hepatitis in 114 patients.

  1975cited by this paper
• [Isoniazid hepatitis].

  1975cited by this paper
• Isoniazid hepatitis.

  1973cited by this paper

• Prevalence of liver function test derangements in adult tuberculosis patients initiated on a daily fixed combination regimen: a prospective study from Kerala, India.

  2026cites this paper
• Elucidating the Mechanism of Modified Yiguanjian against Anti‐Tuberculosis Drug‐Induced Liver Injury via Integrated Pharmacology and Metabolomics

  2026cites this paper
• Risk assessment of trace hydrazine in a 2020 bottled water-associated nonviral hepatitis outbreak.

  2026cites this paper
• Isoliquiritigenin, Nrf2 Activator, and NLRP3 Inhibitor Protects Isoniazid‐Induced Hepatotoxicity in Sprague‐Dawley Rats: Studies on Oxidative Stress, Inflammation, DNA Damage, Ferroptosis, and Steatosis

  2026cites this paper
• Unraveling the Role of CYP2E1 in Antitubercular Drug–Induced Hepatotoxicity: From Molecular Mechanisms to Clinical Implications

  2025cites this paper
• Potensi hepatoprotektif ekstrak daun Euphorbia heterophylla L. dalam menurunkan kadar bilirubin pada tikus Wistar yang diinduksi INH dan rifampisin

  2025cites this paper
• Advances in Antituberculosis Drug-induced Liver Injury: Molecular Mechanisms, Genetic Insights, and Emerging Animal-Free Prediction Models.

  2025cites this paper
• Research Progress on the Etiology of Cholestatic Liver Disease in School-Age Children

  2025cites this paper
• Influence of N-acetyltransferase 2 polymorphisms and clinical variables on liver function profile of tuberculosis patients

  2024cites this paper
• Exploring Variability in Rifampicin Plasma Exposure and Development of Anti-Tuberculosis Drug-Induced Liver Injury among Patients with Pulmonary Tuberculosis from the Pharmacogenetic Perspective

  2024cites this paper
• Effect of NAT2, GSTM1 and CYP2E1 genetic polymorphisms on plasma concentration of isoniazid and its metabolites in patients with tuberculosis, and the assessment of exposure-response relationships

  2024cites this paper
• Toxin-Induced Liver Injury and Extracorporeal Treatment of Liver Failure.

  2024cites this paper
• Fabrication and in vitro–in vivo evaluation of ligand appended isoniazid loaded nanoparticulate systems for the treatment of tuberculosis

  2024cites this paper
• Folic acid protects against isoniazid-induced liver injury via the m6A RNA methylation of cytochrome P450 2E1 in mice

  2024cites this paper
• Clinical Predictors of 3-Months Isoniazid Rifapentine (3HP) - Related Adverse Drug Reactions (ADR) During Tuberculosis Preventive Therapy. (PAnDoRA-3HP study): An Observational Study Protocol

  2024cites this paper
• Precision Medicine Strategies to Improve Isoniazid Therapy in Patients with Tuberculosis

  2024cites this paper
• Isoniazid-historical development, metabolism associated toxicity and a perspective on its pharmacological improvement

  2024cites this paper
• Clinical predictors of 3-month isoniazid rifapentine (3HP)-related adverse drug reactions (ADR) during tuberculosis preventive therapy (PAnDoRA-3HP study): an observational study protocol

  2024cites this paper
• A thiomorpholine substituted malonyl-coumarin dye for discriminative detection of hydrazine and strong acidity

  2023cites this paper
• Molecular mechanism for the involvement of CYP2E1/NF-κB axis in bedaquiline-induced hepatotoxicity.

  2023cites this paper
• Antidotal and protective effects of mangosteen (Garcinia mangostana) against natural and chemical toxicities: A review

  2023cites this paper
• Molecular mechanism for the activation of the potent hepatotoxin acetylhydrazine: Identification of the initial N-centered radical and the secondary C-centered radical intermediates.

  2023cites this paper
• A novel perspective on the preventive treatment of hydrazine compound-induced liver injury: Isoniazid liver injury as an example.

  2023cites this paper
• Liver Injury Following Isoniazid Preventive Therapy in HIV Patients Attending Halibet National Referral Hospital, Eritrea: A Prospective Cohort Study

  2023cites this paper
• Liver injury in children: signal analysis of suspected drugs based on the food and drug administration adverse event reporting system

  2023cites this paper
• Hepatoprotective effect of hydromethanol extract of Otostegia integrifolia benth leaves in isoniazid and rifampicin induced Swiss albino mice

  2023cites this paper
• Benefit of Betaine in Isoniazid-Rifampicin-Induced Hepatotoxicity in Rats

  2023cites this paper
• A dual-response fluorescent probe for N2H4 and viscosity in living cells and zebrafish to evaluate liver injury.

  2022cites this paper
• Isoniazid: An Exploratory Review

  2022cites this paper
• Genetic Variants and Drug Efficacy in Tuberculosis: A Step toward Personalized Therapy

  2022cites this paper
• Antitubercular Therapy-Related Hepatitis

  2022cites this paper
• Time for Isoniazid Pharmacogenomic-Guided Therapy of Tuberculosis Based on NAT2 Acetylation Profiles in India

  2022influential citation
• Role of Pharmacogenomics in Reducing the Risk of Drug-Related Iatrogenesis

  2022cites this paper
• Quantitative Analysis of Isoniazid and Its Four Primary Metabolites in Plasma of Tuberculosis Patients Using LC-MS/MS

  2022cites this paper
• Anti-tuberculosis Drug Induced Hepatotoxicity

  2022cites this paper
• ISONIAZID-INDUCED LIVER INJURY: PHARMACOGENETIC ASPECTS

  2022cites this paper
• Phytochemical screening and toxicity investigation of hydro-methanolic and aqueous extracts from aerial parts of Sonchus oleraceus L. in Swiss albino mice

  2022cites this paper
• Noninvasive in vivo optical imaging models for safety and toxicity testing

  2021cites this paper
• (NASPGHAN) Position Paper on the Diagnosis and Management of Pediatric Acute Liver Failure

  2021cites this paper
• Roselle (Hibiscus sabdariffa L.) calyx water extract ameliorates isoniazid and rifampicin induced liver and renal injuries in rats

  2021cites this paper
• Transporter, Drug Metabolism, and Drug‐Induced Liver Injury in Marketed Drugs

  2021cites this paper
• Hepatoprotective Effect of Corm of Ensete ventricosum (Welw.) Cheesman Extract against Isoniazid and Rifampicin Induced Hepatotoxicity in Swiss Albino Mice

  2021cites this paper
• North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition Position Paper on the Diagnosis and Management of Pediatric Acute Liver Failure

  2021cites this paper
• Exploration of inhibition potential of isoniazid and its metabolites towards CYP2E1 in human liver microsomes through LC-MS/MS analysis.

  2021cites this paper
• Isoniazid Population Pharmacokinetics and Dose Recommendation for Korean Patients With Tuberculosis Based on Target Attainment Analysis

  2021cites this paper
• Isoniazid treatment in children and comparison of tuberculin skin test values before and after treatment

  2021cites this paper
• Dietary Intake of Vegetables and Cooking Oil Was Associated With Drug-Induced Liver Injury During Tuberculosis Treatment: A Preliminary Cohort Study

  2021cites this paper
• Fasting Enhances Biochemical and Histopathological Changes of Isoniazid Induced Liver Injury in Mouse

  2021cites this paper
• The ethanol extract of Garcinia mangostana L peel reduces the isoniazid-induced liver damage in rats

  2021cites this paper
• Toxicity studies of highly bioavailable isoniazid loaded solid lipid nanoparticles as per Organisation for Economic Co-operation and Development (OECD) guidelines.

  2021cites this paper
• Hepatoprotective Bile Acid Co-Drug of Isoniazid: Synthesis, Kinetics and Investigation of Antimycobacterial Potential

  2020cites this paper
• Co-drug of isoniazid and sulfur containing antioxidant for attenuation of hepatotoxicity and treatment of tuberculosis

  2020cites this paper
• An intervalence complex on chitosan surface and its application for isoniazid detection in synthetic samples

  2020cites this paper
• Pyridoxal isonicotinoyl hydrazone inhibition of FXR is involved in the pathogenesis of isoniazid-induced liver injury.

  2020cites this paper
• Determination of isoniazid acetylation patterns in tuberculosis patients receiving DOT therapy under the Revised National tuberculosis Control Program (RNTCP) in India

  2020cites this paper
• A hepatocyte-targeting fluorescent probe for imaging isoniazid-induced hydrazine in HepG2 cells and zebrafish.

  2020cites this paper
• Antitubercular Drug Induced Hepatotoxicity: A Review

  2020cites this paper
• Pharmacogenomics of Drug-Induced Liver Injury

  2020cites this paper
• Possible role for acetylcysteine as a treatment for acute liver failure secondary to antitubercular medication use.

  2020cites this paper
• Oxidations of Benzhydrazide and Phenylacetic Hydrazide by Hexachloroiridate(IV): Reaction Mechanism and Structure–Reactivity Relationship

  2020cites this paper
• Effect of Jamblang (Syzygium cumini) Seed Extract on ALT and AST Levels in Isoniazid-induced Male Rats

  2019cites this paper
• Investigations on the Influence of Zidovudine in the Pharmacokinetics of Isoniazid and Its Hepatotoxic Metabolites in Rats

  2019cites this paper
• Possible Pathways of Hepatotoxicity Caused by Chemical Agents.

  2019cites this paper
• Halloysite nanotubes as tools to improve the actual challenge of fixed doses combinations in tuberculosis treatment.

  2019cites this paper
• Prophylactic Therapy of Silymarin (Milk Thistle) on Antituberculosis Drug-Induced Liver Injury: A Meta-Analysis of Randomized Controlled Trials

  2019cites this paper
• Hepatoprotective effect of Carica Papaya and Ficus Bengalensis Latex in Isoniazid as an antituberculosis drug Induced liver injury in Rats

  2019cites this paper
• Protective Roles of Kolaviron Extract from Garcinia kola Seeds against Isoniazid-induced Kidney Damage in Wistar Rats

  2019cites this paper
• The effect of Garcinia mangostana L rind ethanol extract on transminase liver enzymes and Bilirubin on liver fibrosis rat model

  2019cites this paper
• Solid lipid nanoparticles for ocular delivery of isoniazid: evaluation, proof of concept and in vivo safety & kinetics.

  2019cites this paper
• The role of isoniazid pharmacogenetics in the individualized treatment of tuberculosis

  2019cites this paper
• Telfairia occidentalis (Cucurbitaceae) pulp extract mitigates rifampicin-isoniazid-induced hepatotoxicity in an in vivo rat model of oxidative stress.

  2019cites this paper
• Mitochondrial dysfunction as a mechanism of drug-induced hepatotoxicity: current understanding and future perspectives

  2018cites this paper
• Cytokine-Mediated Systemic Adverse Drug Reactions in a Drug–Drug Interaction Study of Dolutegravir With Once-Weekly Isoniazid and Rifapentine

  2018cites this paper
• Multi-Cellular Organotypic Liver Models for the Investigation of Chemical Toxicity and Liver Fibrosis

  2018cites this paper
• The development and evaluation of a novel hybrid PLGA nanoparticle-Pheroid® with the potential to improve tuberculosis therapy

  2018cites this paper
• Cytoprotective Properties of Carnosine against Isoniazid-Induced Toxicity in Primary Cultured Rat Hepatocytes

  2018cites this paper
• Advances and Challenges of HDAC Inhibitors in Cancer Therapeutics

  2018cites this paper
• Co-infection with hepatitis B virus among tuberculosis patients is associated with poor outcomes during anti-tuberculosis treatment

  2018cites this paper
• Do In Vitro Assays Predict Drug Candidate Idiosyncratic Drug-Induced Liver Injury Risk?

  2018cites this paper
• Amelioration of hepatotoxicity by biocleavable aminothiol chimeras of isoniazid: Design, synthesis, kinetics and pharmacological evaluation

  2018cites this paper
• Pharmacoeconomics of three Therapeutic Schemes for Anti-tuberculosis Therapy Induced Liver Injury in China

  2018cites this paper
• A conjugated-polymer-based ratiometric nanoprobe for evaluating in-vivo hepatotoxicity induced by herbal medicine via MSOT imaging

  2018cites this paper
• New hydrazides derivatives of isoniazid against Mycobacterium tuberculosis: Higher potency and lower hepatocytotoxicity.

  2018cites this paper
• Cell-based assay using glutathione-depleted HepaRG and HepG2 human liver cells for predicting drug-induced liver injury.

  2018cites this paper
• LIFAGO DIELSII SCHWEINF AND MUSCHL (ASTERACEAE) AMELIORATES LIVER INJURY INDUCED BY ISONIAZID AND RIFAMPICIN IN RAT

  2018cites this paper
• Genetic polymorphisms of interleukin-10 and transforming growth factor-β1 and antituberculosis drugs-induced liver injury

  2017cites this paper
• Dexamethasone Pretreatment Alleviates Isoniazid/Lipopolysaccharide Hepatotoxicity: Inhibition of Inflammatory and Oxidative Stress

  2017cites this paper
• Kinetics and mechanism of oxidation of the anti-tubercular prodrug isoniazid and its analog by iridium(iv) as models for biological redox systems.

  2017cites this paper
• Drug-induced liver injury: Do we know everything?

  2017cites this paper
• Is the Prophylactic Use of Hepatoprotectants Necessary in Anti-Tuberculosis Treatment?

  2017cites this paper
• Limited sampling strategies for determining the area under the plasma concentration-time curve for isoniazid might be a valuable approach for optimizing treatment in adult patients with tuberculosis.

  2017cites this paper
• Deficiency of N‐acetyltransferase increases the interactions of isoniazid with endobiotics in mouse liver

  2017cites this paper
• Clinical and experimental research in antituberculosis drug-induced hepatotoxicity: a review.

  2017cites this paper
• Biotransformation of Isoniazid by Cytochromes P450: Analyzing the Molecular Mechanism using Density Functional Theory.

  2017cites this paper
• Development of a modified lymphocyte transformation test for diagnosing drug-induced liver injury associated with an adaptive immune response

  2017cites this paper
• Association and clinical utility of NAT2 in the prediction of isoniazid-induced liver injury in Singaporean patients

  2017cites this paper
• Isoniazid clearance is impaired among human immunodeficiency virus/tuberculosis patients with high levels of immune activation

  2017cites this paper
• Isoniazid inhibits human erythroid 5-aminolevulinate synthase: Molecular mechanism and tolerance study with four X-linked protoporphyria patients.

  2017cites this paper
• Protein Targets of Isoniazid-Reactive Metabolites in Mouse Liver in Vivo.

  2016cites this paper
• PharmGKB summary: isoniazid pathway, pharmacokinetics

  2016cites this paper